A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Latest Information Update: 16 May 2024
At a glance
- Drugs Cobimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 032
- Sponsors Bristol-Myers Squibb
- 08 May 2024 Planned End Date changed from 30 May 2024 to 31 Oct 2024.
- 25 Apr 2024 This trial has been completed in Finland.
- 19 Jan 2024 This trial has been completed in Denmark.